Show simple item record

dc.contributor.authorKayentao, Kassoum
dc.contributor.authorDoumbo, Ogobara K
dc.contributor.authorPénali, Louis K
dc.contributor.authorOffianan, André T
dc.contributor.authorBhatt, KM
dc.contributor.authorKimani, Joshua
dc.contributor.authorTshefu, Antoinette K
dc.contributor.authorKokolomami, Jack HT
dc.contributor.authorRamharter, Michael
dc.contributor.authorde Salazar, Pablo Martinez
dc.contributor.authorTiono, Alfred B
dc.contributor.authorOuédraogo, Alphonse
dc.contributor.authorBustos, Maria Dorina G
dc.contributor.authorQuicho, Frederick
dc.contributor.authorBorghini-Fuhrer, Isabelle
dc.contributor.authorDuparc, Stephan
dc.contributor.authorShin, Chang-Sik
dc.contributor.authorFleckenstein, Lawrence
dc.date.accessioned2013-03-19T15:38:04Z
dc.date.available2013-03-19T15:38:04Z
dc.date.issued2012-10-31
dc.identifier.citationMalaria Journal. 2012 Oct 31;11(1):364
dc.identifier.urihttp://dx.doi.org/10.1186/1475-2875-11-364
dc.identifier.urihttp://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/14671
dc.description.abstractAbstract Background Children are most vulnerable to malaria. A pyronaridine-artesunate pediatric granule formulation is being developed for the treatment of uncomplicated Plasmodium falciparum malaria. Methods This phase III, multi-center, comparative, open-label, parallel-group, controlled clinical trial included patients aged ≤12 years, bodyweight ≥5 to <25 kg, with a reported history of fever at inclusion or in the previous 24 h and microscopically-confirmed uncomplicated P. falciparum malaria. Patients were randomized (2:1) to pyronaridine-artesunate granules (60/20 mg) once daily or artemether-lumefantrine crushed tablets (20/120 mg) twice daily, both dosed by bodyweight, orally (liquid suspension) for three days. Results Of 535 patients randomized, 355 received pyronaridine-artesunate and 180 received artemether-lumefantrine. Day-28 adequate clinical and parasitological response (ACPR), corrected for re-infection using polymerase chain reaction (PCR) genotyping (per-protocol population) was 97.1% (329/339; 95% CI 94.6, 98.6) for pyronaridine-artesunate; 98.8% (165/167; 95% CI 95.7, 99.9) for artemether-lumefantrine. The primary endpoint was achieved: pyronaridine-artesunate PCR-corrected day-28 ACPR was statistically significantly >90% (P < .0001). Pyronaridine-artesunate was non-inferior to artemether-lumefantrine: treatment difference -1.8% (95% CI -4.3 to 1.6). The incidence of drug-related adverse events was 37.2% (132/355) with pyronaridine-artesunate, 44.4% (80/180) with artemether-lumefantrine. Clinical biochemistry results showed similar mean changes versus baseline in the two treatment groups. From day 3 until study completion, one patient in each treatment group had peak alanine aminotransferase (ALT) >3 times the upper limit of normal (ULN) and peak total bilirubin >2xULN (i.e. within the Hy’s law definition). Conclusions The pyronaridine-artesunate pediatric granule formulation was efficacious and was non-inferior to artemether-lumefantrine. The adverse event profile was similar for the two comparators. Pyronaridine-artesunate should be considered for inclusion in paediatric malaria treatment programmes. Trial registration ClinicalTrials.gov: identifier NCT00541385
dc.titlePyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial
dc.typeJournal Article
dc.date.updated2013-03-19T15:38:04Z
dc.description.versionPeer Reviewed
dc.language.rfc3066en
dc.rights.holderKassoum Kayentao et al.; licensee BioMed Central Ltd.


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record